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Background
Melanoma is the most aggressive skin cancer due to its
high metastatic propensity and resistance to most tradi-
tional chemotherapeutic drugs [1,2]. At early stage mela-
noma can be cured by surgical excision, whereas
metastatic melanoma is a highly lethal condition. To
understand melanoma progression is crucial identify
mutations that are involved in making an individual
melanoma competent for metastatic spread. The most
frequent known oncogenic mutation in melanoma is
BRAF-V600E and several whole exome sequencing stu-
dies have revealed numerous other alterations [3-6]. It is
well established that the aggressive behavior of mela-
noma is highly correlated with histological features,
such as the thickness of the primary tumor and the
mitotic index. Here we performed whole exome sequen-
cing of 5 thin (<1mm in thickness) and 5 thick (>4mm
in thickness) primary melanomas compared to matched-
normal DNA.
Materials and methods
We have collected 10 fresh primary melanomas from 10
untreated patients: DNA samples from melanoma tis-
sues and peripheral blood (normal DNA) were available
from all of the recruited patients. Genomic DNA was
extracted from tumor and peripheral blood samples
using the QIAamp DNA Minikit, (Qiagen, Hilden, Ger-
many). Extracted DNA was used for Next-Generation
Sequencing analysis by Illumina.
Results
We confirmed recurrent somatic mutations in known
melanoma-related genes, including BRAF, c-KIT, EGFR,
PPP6C, MLL3 and several components of the glutamate
signaling. In addition, we discovered mutations in genes
not previously linked to this tumor, such as CSMD1,
FGFR4 and components of the Hedgehog (HH) signal-
ing pathway. In particular, in a thick melanoma we
found a novel activating mutation in the transcription
factor GLI1, one of the final effectors of the HH signal-
ing. Additionally, we identified candidate metastasis-
driving mutations such as ADAMTS6, ADAMTS7,
CHD9, MLL3, NALCN and TSC2 in the 3 thick mela-
nomas that produced metastasis. Interestingly, we iden-
tified several regions of focal somatic copy-number
alterations (SCNAs) that were altered at significantly
higher frequency in thick compared to thin melanomas.
Several gene families are comprised among these regions
of focal SCNAs, including components of Notch, HH
and Wnt/b-catenin signaling pathways, BRAF, c-MYC
and its cofactor PIM1, several ADAMs, EGFR and the
HOX genes.
Conclusion
Our data identify potential drivers of melanoma pro-
gression, enhancing our understanding of the genomic
complexity underlying melanoma.
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